Verrica Pharmaceuticals Inc (NASDAQ: VRCA) kicked off on Friday, up 35.62% from the previous trading day, before settling in for the closing price of $6.71. Over the past 52 weeks, VRCA has traded in a range of $3.28-$13.60.
A company in the Healthcare sector has dropped its sales by -5.46% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 93.58%. With a float of $0.85 million, this company’s outstanding shares have now reached $9.49 million.
Verrica Pharmaceuticals Inc (VRCA) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Verrica Pharmaceuticals Inc is 59.64%, while institutional ownership is 29.45%. The most recent insider transaction that took place on Nov 25 ’25, was worth 10,000. In this transaction CMO of this company bought 2,357 shares at a rate of $4.24, taking the stock ownership to the 2,357 shares. Before that another transaction happened on Nov 25 ’25, when Company’s Interim CFO bought 3,536 for $4.24, making the entire transaction worth $15,001. This insider now owns 8,962 shares in total.
Verrica Pharmaceuticals Inc (VRCA) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -2.01 earnings per share (EPS), higher than consensus estimate (set at -2.42) by 0.41. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.58 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 93.58% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 57.83% during the next five years compared to -5.46% drop over the previous five years of trading.
Verrica Pharmaceuticals Inc (NASDAQ: VRCA) Trading Performance Indicators
Take a look at Verrica Pharmaceuticals Inc’s (VRCA) current performance indicators. Last quarter, stock had a quick ratio of 1.11. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.80.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.44, a number that is poised to hit -0.68 in the next quarter and is forecasted to reach -1.61 in one year’s time.
Technical Analysis of Verrica Pharmaceuticals Inc (VRCA)
Let’s dig in a bit further. During the last 5-days, its volume was 0.94 million. That was better than the volume of 0.13 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 94.42%.
During the past 100 days, Verrica Pharmaceuticals Inc’s (VRCA) raw stochastic average was set at 88.97%, which indicates a significant increase from 88.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.68 in the past 14 days, which was higher than the 0.51 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.23, while its 200-day Moving Average is $5.47. However, in the short run, Verrica Pharmaceuticals Inc’s stock first resistance to watch stands at $10.31. Second resistance stands at $11.51. The third major resistance level sits at $13.21. If the price goes on to break the first support level at $7.41, it is likely to go to the next support level at $5.71. Assuming the price breaks the second support level, the third support level stands at $4.51.
Verrica Pharmaceuticals Inc (NASDAQ: VRCA) Key Stats
The company with the Market Capitalisation of 86.36 million has total of 9,490K Shares Outstanding. Its annual sales at the moment are 7,570 K in contrast with the sum of -76,580 K annual income. Company’s last quarter sales were recorded 14,340 K and last quarter income was -270 K.
